Popular search terms:
Search Results
12 results found-
CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.cslseqirus.us/expertise -
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.cslseqirus.us/our-company/leadership -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.us/our-company -
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.cslseqirus.us/our-company/leadership/gregg-sylvester -
Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)
https://www.cslseqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response -
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
https://www.cslseqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines -
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
https://www.cslseqirus.us/news/the-university-of-queensland-cepi-and-csl-partner-on-covid-19-vaccine-candidate -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news/covid19-update -
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
https://www.cslseqirus.us/news/seqirus-is-first-to-market-with-shipment-of-seasonal-influenza-vaccines-for-2016-2017-season -
About Seqirus Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG.
https://www.cslseqirus.us/-/media/seqirus-us/news/franchise-shipment-press-release--71116final-530-pm.pdf